+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immuno-Oncology - Thematic Research

  • PDF Icon


  • 167 Pages
  • May 2022
  • Region: Global
  • GlobalData
  • ID: 5632234
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer. Checkpoint modulation is the most valuable IO sector. Within 2021-2022, the next immuno-oncology breakthrough has not happened. High cost of therapy and need for personalized treatment using biomarkers remain as unmet needs.


  • Overview of immuno-oncology including classification of therapy and technologies, regulatory and market access details, product & company profiles.
  • Quotes from US- and 5EU-based key opinion leaders and payers.
  • Key topics covered for IO in the 8MM include trends, value chain, market analysis, opportunities, challenges and unmet needs and high-value deals.
  • Pipeline analysis: Comprehensive data split across different phases and indications, emerging novel trends under development, and analysis of the most promising late-stage pipeline drugs for each class of IO (Phase II - III).
  • Analysis of the key dynamics of the IO market. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered in detail to highlight business opportunities.
  • Robust analysis of high-prescriber survey conducted with 80 oncologists.

Reasons to Buy

  • What impact will late-stage pipeline agents have on the market? Which class of IO drugs will have the highest peak sales, and why?
  • What are the current unmet needs in IO, which pipeline agents or strategies are positioned to counter these unmet needs? What are the opportunities for R&D?
  • How is the field of checkpoint modulation going to move forward? Which technologies are the most promising for combinations?
  • What is the regulatory landscape for IO agents in the US, the 5EU Japan, and China?
  • What is the current and future outlook of IO according to high prescribers?

Table of Contents

1. Preface
1.1. Table of Contents
1.2. Abbreviations
1.3. Related Reports
2. Executive Summary
2.1. Key Findings
3. Immuno-oncology Overview
3.1. What is Immuno-oncology?
3.2. Most Important Milestones of Immuno-oncology Development Globally
3.3. Key Twitter Chat
4. Trends
4.1. Industry Trends - Bispecific Antibodies
4.2. Industry Trends - Cancer Vaccines
4.3. Industry Trends - Cell Therapies
4.4. Industry Trends - Checkpoint Modulators
4.5. Industry Trends - Cytokines
4.6. Industry Trends - Oncolytic Viruses
4.7. Regulatory Trends
5. Value Chain
5.1. Immuno-oncology Value Chain
5.2. Bispecific Antibodies
5.3. Cancer Vaccines
5.4. Cell Therapies
5.5. Checkpoint Modulators
5.6. Cytokines
5.7. Oncolytic Viruses
5.8. Immuno-oncology in Clinical Trials
6. Marketed Products
6.1. Marketed Immuno-oncology Products in the 8MM
6.2. Total Market Size for Immuno-oncology Agents
6.3. Ten Highest-grossing Immuno-oncology Treatments in 2021
6.4. Leading Checkpoint Modulators in The 8MM
6.5. Leading Cancer Vaccines, Bispecific Antibodies and Oncolytic Viruses in The 8MM
6.6. Leading Cell Therapies in The 8MM
7. Pipeline Products
7.1. Immuno-oncology Pipeline Products in the 8MM
7.2. Pipeline Products by Type and Phase
7.3. Future Outlook of Immuno-oncology Agents According to High-Prescribing Physicians
7.4. Consensus Forecast Sales for the Top Products per Class of Immuno-oncology
7.5. Late Stage Bispecific Antibody Products
7.6. Late Stage Cancer Vaccine Products
7.7. Late Stage Cell Therapy Products
7.8. Late Stage Checkpoint Modulator Products
7.9. Late Stage Cytokine Products
7.10. Late Stage Oncolytic Virus Products
8. Market Analysis and Deals
8.1. Immuno-oncology Market Analysis and Forecast by Class of Therapy
8.2. Top 10 Strategic Partnership Deals by Size in the Immuno-oncology Space
8.3. Latest Strategic Partnership Deals in the Immuno-oncology Space
8.4. Mergers and Acquisitions That Include Immuno-oncology Assets: 2020 - 2021
8.5. Mergers and Acquisitions That Include Immuno-oncology Assets: 2016 - 2020
9. Regulatory and Market Access
9.1. Immuno-oncology in Clinical Trials
9.2. Differences in Immuno-oncology Clinical Trials - KOLs Perspective
9.3. Challenges in Immuno-oncology Clinical Trials - KOLs Perspective
9.4. Regulatory and Market Access - US
9.5. Regulatory and Market Access - Europe
9.6. Regulatory and Market Access - Japan
9.7. Regulatory and Market Access - China
9.8. Comparison of Early Access Schemes in the US, EU, Japan, and China
9.9. Barriers to Access According to High Prescribers
10. Opportunities, Challenges, and Unmet Needs
10.1. Bispecific Antibodies - Opportunities & Challenges
10.2. Cancer Vaccines - Opportunities & Challenges
10.3. Cell Therapies- Opportunities & Challenges
10.4. Checkpoint Modulators - Opportunities & Challenges
10.5. Cytokines - Opportunities & Challenges
10.6. Oncolytic Viruses - Opportunities & Challenges
10.7. Clinical Unmet Needs in Immuno-oncology - Gap Analysis
10.8. Commercial Unmet Needs in Immuno-oncology - Gap Analysis
10.9. Unmet Needs - KOLs Perspective
10.10. Unmet Needs According to High Prescribers
10.11. R&D Strategies
10.12. Opportunities According to KOLs and Closing Remarks
11. Companies
12. Appendix
12.1. Sources
12.2. Primary Research
12.3. Key Themes Impacting the Pharmaceutical Industry
12.4. Our Thematic Research Methodology
12.5. About the Authors
12.6. Contact the Publisher
12.7. Disclaimer

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Novartis
  • Merck & Co
  • Gilead
  • Roche
  • Bristol-Myers Squibb
  • AstraZeneca
  • Sanofi
  • Amgen
  • Dendreon Pharmaceuticals
  • Legend Biotech
  • Johnson & Johnson
  • Alphamab
  • Genmab
  • Regeneron
  • Iovance Biotherapeutics
  • Replimune
  • Oncolytics
  • Inovio
  • VBI Vaccines
  • Instil Bio
  • Alaunos Therapeutics
  • Jounce Therapeutics
  • Arcus Biosciences
  • Neoleukin Therapeutics
  • Alkermes
  • Oncosec
  • Oncorus